Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Francesca Bruce

Senior Writer

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.

Latest From Francesca Bruce

English & Scottish HTAs Diverge On Sanofi’s Dupixent For Rare Skin Condition

The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.

Europe United Kingdom

BMS Secures Better HTA Result In Germany With Additional Data for Camzyos

A revised benefit rating for BMS’ cardiomyopathy drug Camzyos will be good news for the product’s pricing in Germany.

Europe Germany

Mexico Launches ‘Regulatory Certainty Strategy’ For Biosimilars

Mexico is to establish a new regulatory framework that is in line with international standards to encourage domestic production of biosimilar medicines.

Mexico Biosimilars

Mexico Launches ‘Regulatory Certainty Strategy’ For Biosimilars

Mexico is to establish a new regulatory framework that is in line with international standards to encourage domestic production of biosimilar medicines. 

North America Mexico

ABPI Presents Pre-Election Vision For Boosting UK Clinical Trials, Innovation & Manufacturing

The ABPI’s “manifesto for investment, health and growth” says that the new government to be elected later this year must ensure that investment in new medicines and research accelerates future innovation and attracts more R&D to the UK.

Europe United Kingdom

Life Sciences In The Spotlight As UK Prepares For General Election

The opposition Labour Party’s life sciences plan aims to make the UK a “frontier market” for innovative products, including cell and gene therapies. 

Europe United Kingdom
See All
UsernamePublicRestriction

Register